This CPB has been revised to: (i) restructure the criteria and nomenclature for Evenity (romosozumab-aqqg) therapy, (ii) add the following: appendices for clinical reasons to avoid oral bisphosphonate therapy and the WHO fracture risk assessment tool, dosing recommendations section, criteria for continuation of Evenity therapy, and (iii) update the references.